Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance. The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management. Read More
Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.
Aditxt, Inc. requests that their press release NewsItemId: 20250417385764 “Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™” be killed.
Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100, the lead therapeutic candidate from Aditxt’s subsidiary, Adimune Inc. The update will also feature Dr. Shahrokh Shabahang, Aditxt’s Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune, highlighting the latest advancements in immune modulation therapy.
Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received Institutional Review Board approval to initiate a clinical study evaluating the Mitomic Endometriosis Test (MET), a blood-based diagnostic aimed at early detection of endometriosis. The study will enroll up to 1,000 participants beginning in May 2025 and compare MET results to laparoscopic diagnoses, the current standard. Designed to detect mitochondrial DNA deletions, MET offers a non-invasive approach that could reduce diagnostic delays impacting millions of women globally. Results may support the test’s launch as a Laboratory Developed Test from Pearsanta’s certified lab.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will provide key updates on recent events, including:
Aditxt (NASDAQ: ADTX) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), eliminating the need for a previously scheduled hearing with the exchange’s Hearings Panel. The company’s stock will continue trading on the Nasdaq Capital Market under the ticker ADTX as it advances health innovation efforts targeting autoimmunity, cancer, and other major health challenges.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel scheduled to take place on April 22, 2025, has been cancelled. The Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol ADTX.
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health breakthroughs, announced that Don Cilla, Pharm.D., M.B.A., CEO of Appili Therapeutics, will join its Weekly Update on April 4 at 11:30 a.m. ET. The session will spotlight the growing need for infectious disease treatments and explore how partnerships like Aditxt and Appili’s can fast-track health innovations. The discussion will also detail Appili’s $33.2 million in non-dilutive funding, $117 million in new applications, and updates to its U.S. Air Force Academy agreement supporting ATI-1701, a biodefense vaccine candidate.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatments, and the role of partnerships in accelerating promising health innovations.
Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health technologies, announced that its latest Aditxt Weekly Update will spotlight the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The proprietary technology, based on adductomics, is engineered to detect early DNA changes that could lead to cancer and other diseases. The discussion will emphasize how the CaSe Platform supports Pearsanta’s mission of advancing early detection and prevention in oncology. Featured participants include Dr. Shahrokh Shabahang of Aditxt, Chris Mitton of Pearsanta, and Dr. Roger Giese, the platform’s co-inventor.
Aditxt, Inc. (NASDAQ: ADTX), (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. (“Pearsanta”). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussion will explore the platform’s role in advancing Pearsanta’s mission to address cancer through early detection and prevention.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, Inc., has acquired key patents for adductomics-based DNA damage detection in a $1 million stock transaction. The move expands Pearsanta’s capabilities in early cancer risk assessment, complementing its existing Mitomic® Technology. The acquired technology detects DNA adducts—early markers of carcinogen exposure—allowing for potential cancer prevention strategies before permanent mutations develop. Pearsanta plans to advance clinical validation and regulatory pathways over the next two to three years, aiming to commercialize the diagnostics through CLIA/CAP-certified labs.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
